Tamoxifen in Axillary Node-Negative Breast Cancer: Multisystem Benefits and Risks
作者:
LoveRichard R.,
期刊:
Cancer Investigation
(Taylor Available online 1992)
卷期:
Volume 10,
issue 6
页码: 587-593
ISSN:0735-7907
年代: 1992
DOI:10.3109/07357909209024821
出版商: Taylor&Francis
数据来源: Taylor
摘要:
Adjuvant tamoxifen therapy is associated with modest improvement in disease-free and overall survival in women with invasive axillary node-negative breast cancer. The preponderance of data supporting these general conclusions are from trials in postmenopausal women; in premenopausal women data appear convincing regarding disease-free, hut not overall, survival. Firm conclusions regarding magnitude of benefit related to presence of different prognostic factors cannot be drawn at present.In postmenopausal women tamoxifen appears to alter favorably some risk factors for cardiovascular diseases and osteoporosis, which are the most common causes of mortality or morbidity in older American women. Adjuvant tamoxifen is associated with a significantly reduced risk of second primary breast cancer. Major serious risks of tamoxifen therapy include depression, and possibly thrombophlebitis and uterine endometrial cancer. Symptomatic vasomotor and gynecological side effects are frequent. Decision making with women should include assessment of these multisystem benefits and risks.
点击下载:
PDF (612KB)
返 回